Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.
Inhibitors are an uncommon complication of mild haemophilia A but represent a severe disease, typically with high titre inhibitors and an associated high rate of bleeding. We present data from three patients with MHAI who were successfully treated with Rituximab alone and unequivocally prove that such inhibitors respond to this agent. A treatment protocol is suggested.
Dunkley
S
S
Haemophilia and Thrombosis Unit, Royal Prince Alfred Hospital, Sydney, Australia. scott.dunkley@email.cs.nsw.gov.au
Kershaw
G
G
Young
G
G
Warburton
P
P
Lindeman
R
R
Matthews
S
S
Rennisson
F
F
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab